The first-year growth response to growth hormone treatment predicts the long-term prepubertal growth response in children

BMC Medical Informatics and Decision Making

Volumn 9, Issue 1, 2009, Pages

  Kriström, Berit ^a,b   Dahlgren, Jovanna ^a   Niklasson, Aimon ^a   Nierop, Andreas Fm ^c   Albertsson Wikland, Kerstin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c Muvara   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE;

ADOLESCENT; ARTICLE; CHILD; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GROWTH; HUMAN; MALE; OUTCOME ASSESSMENT; STATISTICAL MODEL; VALIDATION STUDY;

ADOLESCENT; CHILD; FEMALE; GROWTH; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; MALE; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 61849167366     PISSN: None     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-9-1     Document Type: Article

References (27)

1. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. MB Ranke A Lindberg P Chatelain P Wilton W Cutfield K Albertsson-Wikland DA Price, J Clin Endocrinol Metab 1999 84 1174 1183 10.1210/jc.84.4.1174 10199749
2. Validated multivariate models predicting the growth response to GH treatment in individual short children with a broad range in GH secretion capacities. K Albertsson-Wikland B Kristrom S Rosberg B Svensson AF Nierop, Pediatr Res 2000 48 475 484 10.1203/00006450-200010000-00010 11004238
3. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). MB Ranke A Lindberg CT Cowell K Albertsson-Wikland EO Reiter P Wilton DA Price, J Clin Endocrinol Metab 2003 88 125 131 10.1210/jc.2002-020867 12519840
4. Validation and calibration of the Kabi Pharmacia International Growth Study prediction model for children with idiopathic growth hormone deficiency. MA de Ridder T Stijnen AC Hokken-Koelega, J Clin Endocrinol Metab 2003 88 1223 1227 10.1210/jc.2002-021244 12629110
5. Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational age. J Dahlgren B Kristrom A Niklasson AF Nierop S Rosberg K Albertsson-Wikland, BMC Med Inform Decis Mak 2007 7 40 18076760 10.1186/1472-6947-7-40
6. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. MB Ranke A Lindberg DA Price F Darendeliler K Albertsson-Wikland P Wilton EO Reiter, Horm Res 2007 68 53 62 10.1159/000098707 17228181
7. Effect of growth hormone (GH) treatment on the near-final height of 1258 patients with idiopathic GH deficiency: analysis of a large international database. EO Reiter DA Price P Wilton K Albertsson-Wikland MB Ranke, J Clin Endocrinol Metab 2006 91 6 2047 54 10.1210/jc.2005-2284 16537676
8. Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. C Jansson C Boguszewski S Rosberg L Carlsson K Albertsson-Wikland, Clin Chem 1997 43 950 956 9191545
9. Growth in full-term small-for-gestational-age infants: from birth to final height. J Karlberg K Albertsson-Wikland, Pediatr Res 1995 38 5 733 739 10.1203/00006450-199511000-00017 8552442
10. An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977-1981). A Niklasson A Ericson JG Fryer J Karlberg C Lawrence P Karlberg, Acta Paediatr Scand 1991 80 756 762 10.1111/j.1651-2227.1991.tb11945.x 1957592
11. New refererence for Swedish infants' size at birth. A Niklasson P Karlberg, Horm Res 1999 51 suppl 2 10505084
12. On the modelling of human growth. J Karlberg, Stat Med Mar 1987 6 2 185 92 10.1002/sim.4780060210
13. Swedish population-based longitudinal reference values from birth to 18 years of age for height, weight and head circumference. K Albertsson-Wikland ZC Luo A Niklasson J Karlberg, Acta Paediatr 2002 91 739 754 10.1080/08035250213216 12200898
14. Seasonality in lower leg length velocity in prepubertal children. L Gelander J Karlberg K Albertsson-Wikland, Acta Paediatr 1994 83 12 1249 1254 10.1111/j.1651-2227.1994.tb13006.x 7734863
15. Final height in a large cohort of Dutch patients with growth hormone deficiency treated with growth hormone. Dutch Growth Hormone Working Group. B Rikken GG Massa JM Wit, Horm Res 1995 43 135 137 10.1159/000184259 7750914
16. Adult height in growth hormone (GH)-deficient children treated with biosynthetic GH. The Genentech Growth Study Group. SL Blethen J Baptista J Kuntze T Foley S LaFranchi A Johanson, J Clin Endocrinol Metab 1997 82 418 420 10.1210/jc.82.2.418 9024229
17. Effect of growth hormone (GH) during puberty in GH-deficient children: preliminary results from an ongoing randomized trial with different dose regimens. K Albertsson-Wikland F Alm S Aronsson J Gustafsson L Hagenas A Hager S Ivarsson B Kristrom C Marcus C Moell KO Nilsson M Ritzen T Tuvemo U Westgren O Westphal J Aman, Acta Paediatr Suppl 1999 88 80 84 10.1111/j.1651-2227.1999. tb14358.x 10102059
18. Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growth hormone deficiency. Analysis of 195 Patients of the Kabi Pharmacia International Growth Study. MB Ranke DA Price K Albertsson-Wikland M Maes A Lindberg, Horm Res 1997 48 62 71 10.1159/000185487 9251922
19. Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency. C Land WF Blum A Stabrey E Schoenau, Eur J Endocrinol 2005 152 727 733 10.1530/eje.1.01899 15879358
20. The potential of prediction models based on data from KIGS as tools to measure responsiveness to growth hormone. Pharmacia International Growth Database. MB Ranke A Lindberg P Chatelain P Wilton DA Price K Albertsson-Wikland, Horm Res 2001 55 Suppl 2 44 48 10.1159/000063474 11684876
21. Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. P Cohen GM Bright AD Rogol AM Kappelgaard RG Rosenfeld, J Clin Endocrinol Metab 2002 87 90 98 10.1210/jc.87.1.90 11788629
22. IGF-based dosing of GH therapy in children: A randomized controlled study. P Cohen AD Rogol CP Howard GM Bright AM Kappelgaard RG Rosenfelt, J Clin Endocrinol Metab 2007 92 7 2480 2486 10.1210/jc.2007-0204 17356043
23. Survey of growth hormone treatment practices by 251 pediatric endocrinologists. DT Wyatt D Mark A Slyper, J Clin Endocrinol Metab 1995 80 3292 3297 10.1210/jc.80.11.3292 7593441
24. Growth prediction models, concept and use. B Kriström K Albertsson-Wikland, Horm Res 2002 57 Suppl 2 66 70 12065931
25. Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment. B Kristrom C Jansson S Rosberg K Albertsson-Wikland, J Clin Endocrinol Metab 1997 82 2889 2898 10.1210/jc.82.9.2889 9284715
26. Radioimmunoassays for IGFs and IGFBPs. WF Blum BH Breier, Growth Regul 1994 4 Suppl 1 11 19 7515738
27. Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. C Löfqvist E Andersson L Gelander S Rosberg WF Blum K Albertsson-Wikland, J Clin Endocrinol Metab 2001 86 5870 5876 10.1210/jc.86.12.5870 11739455